ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 06:08:39 +00:00222, 10 Aug 2025 06:08:39 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 06:08:22 +00:00222, 10 Aug 2025 06:08:22 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 06:08:08 +00:00222, 10 Aug 2025 06:08:08 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 06:08:28 +00:00222, 10 Aug 2025 06:08:28 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 06:08:74 +00:00222, 10 Aug 2025 06:08:74 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 06:08:95 +00:00222, 10 Aug 2025 06:08:95 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 07:08:05 +00:00222, 10 Aug 2025 07:08:05 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 07:08:79 +00:00222, 10 Aug 2025 07:08:79 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 07:08:40 +00:00222, 10 Aug 2025 07:08:40 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 07:08:73 +00:00222, 10 Aug 2025 07:08:73 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 07:08:27 +00:00222, 10 Aug 2025 07:08:27 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 07:08:36 +00:00222, 10 Aug 2025 07:08:36 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 07:08:53 +00:00222, 10 Aug 2025 07:08:53 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org222, 10 Aug 2025 07:08:86 +00:00222, 10 Aug 2025 07:08:86 +00:00FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the LINKER-MM1 study</p>noreply@esmo.org600b6d5b-879b-4e80-acff-058732ba42baFri, 08 Aug 2025 07:08:00 +00:00EMA Recommends Extension of Therapeutic Indications for Darolutamide https://www.esmo.orgnull<p>New indication concerns treatment of adult men with hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy</p>noreply@esmo.org6dd4f420-b8ec-4e7a-b385-2a95bac1a59fThu, 07 Aug 2025 07:08:00 +00:00Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms https://www.esmo.orgnull<p>Findings from the SAVANNAH study</p>noreply@esmo.org0768d2cf-822b-4c80-8429-f0b6526e66efWed, 06 Aug 2025 07:08:00 +00:002025 ESMO Society Award recipients announced https://www.esmo.orgnull<p>The recipients of the 2025 ESMO Society Awards have been announced today by ESMO</p>noreply@esmo.org22294c1b-d33b-4571-8e29-11704a73de3dTue, 05 Aug 2025 12:08:00 +00:00Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up https://www.esmo.orgnull<p>Lymphoma management is undergoing rapid development. The new Lymphomas CPG provides evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline.</p>noreply@esmo.org773fb99b-f492-4a36-8275-0b17fafc07b3Tue, 05 Aug 2025 08:08:00 +00:00A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study</p>noreply@esmo.org1fb276a2-6406-4094-8b30-ab90266f9634Tue, 05 Aug 2025 07:08:00 +00:00OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma https://www.esmo.orgnull<p>Findings from the PANOVA-3 study</p>noreply@esmo.orgf0d94d02-0d88-473a-b6a3-c21436e4d462Mon, 04 Aug 2025 07:08:00 +00:00FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ENVISION study</p>noreply@esmo.org9e440e5f-aede-440e-bab4-63af3e096acdThu, 31 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib https://www.esmo.orgnull<p>It is intended for the treatment of plexiform neurofibromas in adults and children from 2 years of age with neurofibromatosis type 1</p>noreply@esmo.orgbd29378e-bf0e-4cf4-b42e-cd7742ab66e1Thu, 31 Jul 2025 07:07:00 +00:00HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours https://www.esmo.orgnull<p>Real-world experience from pan-tumour testing</p>noreply@esmo.org6d3903df-c371-47ba-bbd1-b4cc2080e721Wed, 30 Jul 2025 07:07:00 +00:00Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC https://www.esmo.orgnull<p>Findings from the NeoCOAST-2 study</p>noreply@esmo.org49d634f5-399e-4fd0-ac23-2fac3a92a683Tue, 29 Jul 2025 07:07:00 +00:00Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR https://www.esmo.orgnull<p>Final results from the IMpassion031 study</p>noreply@esmo.orgc1468849-fa18-4c33-a2d0-a81fee5a6dcdMon, 28 Jul 2025 07:07:00 +00:00FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations https://www.esmo.orgnull<p>FDA also approved the Oncomine Dx Express Test as a companion diagnostic device</p>noreply@esmo.orgd8513302-0795-4d77-97e9-ef9eaad4b95aFri, 25 Jul 2025 07:07:00 +00:00EMA Recommends Extension of Indications for Tislelizumab https://www.esmo.orgnull<p>New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma</p>noreply@esmo.org0e1c7dc7-9845-4095-b840-598b96dde59cThu, 24 Jul 2025 07:07:00 +00:00Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone Receptor-Positive Breast Cancer https://www.esmo.orgnull<p>Findings from the POSITIVE study</p>noreply@esmo.orgffa0af5f-e8dc-428c-93d5-7c981f1e97c6Wed, 23 Jul 2025 07:07:00 +00:00Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC https://www.esmo.orgnull<p>Findings from the CREST study</p>noreply@esmo.org096755a0-8480-4031-bf7b-a39c58e36147Tue, 22 Jul 2025 07:07:00 +00:00ESMO Welcomes EU Proposals for MFF & FP10 and Calls for Cancer to Be Prioritised During the 2028-2034 Budget Period https://www.esmo.orgnull<p>To effectively tackle the scourge of cancer across Europe, ESMO calls on European lawmakers to prioritise cancer under the forthcoming long-term budget of the EU and the new research & innovation programme - to the benefit of patients and society at large</p>noreply@esmo.orge70cd8ee-39c8-41ba-9fc6-06cb80df48d8Mon, 21 Jul 2025 07:07:00 +00:00Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours https://www.esmo.orgnull<p>Findings from the TUXEDO-3 study</p>noreply@esmo.orgc82b03e2-7b64-4035-a5f0-41f3f8ea8872Mon, 21 Jul 2025 07:07:00 +00:00FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the KEYNOTE-689 study</p>noreply@esmo.orga82fe047-2056-4802-a748-07e4ddde2891Fri, 18 Jul 2025 07:07:00 +00:00EMA Recommends Extending Indications for Durvalumab https://www.esmo.orgnull<p>New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer</p>noreply@esmo.org9acf25aa-bab8-4d39-bc60-b5d9163196e1Thu, 17 Jul 2025 07:07:00 +00:00